Location of Repository

Carvedilol.

By 

Abstract

Carvedilol is the first beta-blocker to obtain approval for treatment of heart failure. Improvement in hemodynamic parameters was initially documented in three methodologically sound studies involving 156 patients. Follow up was limited to 16 weeks. A placebo-controlled, double-blind trial involving 1094 patients showed beneficial effects on overall mortality of 4.6% in absolute terms after a median follow up of 6.5 months. This benefit was not found in another trial involving 415 patients followed on average for 19 months. Results for symptom-based criteria conflict. When treatment is introduced very gradually, adverse effects (malaise) seem to be minor and infrequent. Carvedilol's place in the treatment of heart failure is not yet precisely documented

Topics: Research Article
Publisher: College of Family Physicians of Canada
OAI identifier: oai:pubmedcentral.nih.gov:2328581
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.